Ask any sommelier who has worked the floor over the past eighteen months and you will hear a version of the same anecdote. A regular customer — usually between 35 and 60, often a confident wine drinker for decades — orders a single glass instead of the usual half-bottle, then leaves most of it. They look slightly puzzled by their own behaviour. Eventually, sometimes at the third or fourth visit, they explain. They started Ozempic in October. Or Wegovy in January. Or Mounjaro after their last check-up. Wine, they say, just does not taste the way it used to.
This is not a wellness fad or a generational shift. It is a measurable pharmacological side effect of one of the fastest-adopted drug classes in modern medicine, and it is now showing up in the structural numbers of European NoLo (no-and-low-alcohol) drinks. The question is no longer whether GLP-1 receptor agonists are reshaping how Europeans drink. The question is how fast, and what the on-trade is going to do about it.
What the science actually says — three studies, three angles
The clinical evidence is now substantive enough to draw cautious conclusions. The most-cited piece is a phase-2, double-blind, randomised trial published in JAMA Psychiatry in February 2025 by Christian Hendershot and colleagues at the University of North Carolina. Forty-eight adults with signs of moderate alcohol-use disorder received either low-dose semaglutide or placebo for nine weeks. Semaglutide did not significantly cut the number of days participants drank, but it did significantly reduce drinks per drinking day, weekly alcohol craving, and the total grams of alcohol consumed in a controlled lab self-administration task — with medium to large effect sizes. A subsample of cigarette smokers also reduced their daily smoking. This was a small trial, but it was the first prospective evidence in humans that low-dose semaglutide reduces actual drinking behaviour, not just self-reported intent.
The second piece is broader and more consumer-facing. A 2024 report from KAM and the UK charity Drinkaware tracked self-reported alcohol behaviour in GLP-1 users and found average drinking days falling from 3.1 per week before treatment to 2.2 per week — a 29% drop in frequency. More tellingly, 18% of users reported actively unpleasant nausea when they drank, the kind of physiological signal that does not just nudge behaviour but rewrites it. People do not learn to enjoy a substance that makes them queasy.
The third piece — and perhaps the one with the most counterintuitive implications — came in September 2025, when Yale School of Medicine researchers published in npj Metabolic Health and Disease. They reported that GLP-1 receptor agonists reduce expression of Cyp2e1, the hepatic enzyme that metabolises alcohol into acetaldehyde, the toxic compound responsible for much of alcohol's damage to the liver. In experimental models, this means GLP-1s offer some hepatic protection even to patients who keep drinking. The catch: the same study found that blood alcohol concentrations rose higher and took longer to clear, meaning a familiar two-drink evening could push someone over a legal driving threshold without their realising it. The mechanism that protects the liver also makes intoxication slower-cleared and less predictable.
Why the wine just stops working
The pharmacology is more elegant than the headlines suggest. GLP-1 (glucagon-like peptide-1) receptor agonists were designed to manage type-2 diabetes and obesity by mimicking a gut hormone that signals satiety, slows gastric emptying, and modulates insulin release. Because GLP-1 receptors are also expressed in brain regions involved in reward processing — particularly the ventral tegmental area and nucleus accumbens — these drugs incidentally dampen the dopamine reward signal that addictive substances exploit. Alcohol is the largest, most-consumed addictive substance on earth, so the effect is hardest to miss.
Layered on top is the gastric mechanism. Slowed gastric emptying means alcohol lingers in the stomach, where it can trigger nausea more easily and where its absorption profile changes. The Yale work suggests that absorption may not be slower in net terms, but the perception of drinking — the warm flush, the loosening, the second-glass dopamine bump — is muted. Wine becomes a sensory experience that no longer pays back what it costs.
Premium NA spirits and craft alcohol-free beers are the most direct beneficiaries of the GLP-1 effect: drinkers who still want a glass in their hand, just without the part that no longer works.
What the European numbers look like
Pharmacology only matters commercially when it shows up in checkout data. By the start of 2026, the signal in European retail is unmistakable.
In Germany — the single largest beer market in the European Union — NielsenIQ data cited by the Deutscher Brauer-Bund showed that alcohol-free beer and alcohol-free mixed beer drinks together exceeded 10% of beer retail turnover for the first time in 2025. Christian Weber, the Brauer-Bund's president, was explicit about the implication: Germany has become Europe's largest market for non-alcoholic beverages. The 10% threshold is by value, not yet by volume — but value crosses first, and volume tends to follow.
In Spain, the trajectory is even more advanced. Cerveceros de España reports that non-alcoholic beer now accounts for 14% of total beer marketed in the country and 16% of beer consumed at home. One in four Spaniards drinks NA beer regularly, and Spain produces and consumes more alcohol-free beer than any other country in Europe — about a quarter of the EU total.
The deal-making confirms what the data shows. Carlsberg's £3.3 billion acquisition of Britvic, completed on 16 January 2025, was about more than gaining a UK soft-drinks portfolio. The combined Carlsberg Britvic explicitly positioned itself as the largest multi-beverage supplier in the UK, with a portfolio designed to absorb the migration from beer to soft drinks, premium tonics, NA beer, and adult soft drinks. By early 2026, Carlsberg's reporting confirmed alcohol-free brews growing roughly 4% in volume — at a time when overall beer volumes were declining.
The next 24 months: what changes for menus
The hospitality response is still uneven, but the direction is clear. Bars and restaurants that designed menus around the assumption that 70-80% of beverage revenue would come from alcoholic drinks are encountering a customer base that, for chemical reasons rather than ideological ones, simply orders less. The premium NA category is no longer the curiosity slot at the bottom of the drinks menu — it is becoming a core revenue line.
What this requires is a re-architected menu. A single token alcohol-free beer is not enough. Customers on GLP-1s tend to want a real choice — a properly made NA aperitif, a credible NA wine pairing, a craft alcohol-free beer that actually rewards attention. The hospitality businesses that are visibly winning this customer segment in 2026 are the ones that built genuine NA depth: three or four NA beers across styles, two or three serious dealcoholized wines, a mocktail menu drafted with the same care as the cocktail menu.
The signal to watch over the next twenty-four months is whether the GLP-1 effect plateaus or compounds. Given that GLP-1 prescriptions across Europe continue to grow at double-digit rates, and that newer compounds (tirzepatide, retatrutide) appear to act on the same reward circuitry with greater potency, the likeliest scenario is compounding. The drinks industry is not facing a temporary headwind — it is facing a structural reset of what a typical European adult of drinking age actually wants in their glass.
Where the data sits: a quick reference
| Source | What it measured | Key finding |
|---|---|---|
| JAMA Psychiatry, Feb 2025 (Hendershot et al.) | 9-week RCT, 48 adults with AUD signs, low-dose semaglutide vs placebo | Significant reduction in drinks per drinking day and weekly craving; medium to large effect on grams of alcohol consumed in lab task |
| KAM × Drinkaware, UK, 2024 | Self-report survey of GLP-1 users | Drinking frequency dropped from 3.1 to 2.2 days per week (-29%); 18% reported nausea when drinking |
| Yale / npj Metabolic Health, Sep 2025 | GLP-1 effect on hepatic alcohol metabolism (animal models) | Lower Cyp2e1 expression → less acetaldehyde → hepatic protection; but higher and longer-lasting blood alcohol levels |
| NielsenIQ + Deutscher Brauer-Bund, 2025 | German beer retail data | Alcohol-free beer + mixed drinks first crossed 10% of retail turnover; Germany now largest NA beverage market in Europe |
| Cerveceros de España, 2025 | Spanish beer consumption | NA beer = 14% of total beer marketed, 16% of at-home consumption; Spain leads EU in NA beer production and consumption |
| Carlsberg, 16 January 2025 | Acquisition of Britvic for £3.3bn | Strategic pivot toward multi-beverage portfolio including NA brews and soft drinks |
What this means for the next time you pour
If you are noticing more "I'll have what they're having, but the zero" moments in your circle, you are not imagining it. The behaviour change is real, the science underwriting it is now peer-reviewed, and the retail data confirms the migration is structural rather than seasonal. The interesting question is no longer whether to take this seriously. It is whether the NoLo category — which is finally producing genuinely good products — can capitalise on the moment by treating these new customers as serious drinkers who want serious drinks, just without the active ingredient that has stopped working for them.
The independent zeroproof.one knowledge base maps the European NA landscape — the producers, the categories, and the market data — for readers, sommeliers and operators who want to understand the shift in depth.
Ozempic was not designed to change how Europe drinks. The fact that it is doing so anyway, alongside Wegovy, Mounjaro and the next generation of GLP-1s already in trials, is one of those quiet pharmacological side stories that ends up reshaping a category. The drinks industry has had a few years' warning. The next two will tell us who actually used them.